Libby's H*O*P*E*

*Helping*Ovarian Cancer Survivors*Persevere Through*Education

Menu

Skip to content
  • Home
  • About
  • Mission
  • Warning Signs & Symptoms
  • Ovarian Cancer Overview
  • Prevention, Early Detection/Screening & Causes
  • Genetics
  • Types of Ovarian Cancer
  • Diagnosis & Staging
  • Treatment Overview
  • Surgery
  • Chemotherapy
  • Radiology & Radiation Therapy
  • Hormonal (Anti-Estrogen) Therapy
  • Biological (Immunotherapy & Vaccine) Therapy
  • Gene Therapy
  • Alternative & Complementary Therapy
  • Clinical Development
  • Clinical Trials
  • Coping
  • Survivorship
  • Ovarian Cancer Resources
  • Contact

Tag Archives: S.M. Janes M.D. Ph.D.

Researchers Are On The TRAIL To Killing Cancer With Genetically-Engineered Adult Stem Cells

Posted on May 21, 2009 by Paul Cacciatore

“Researchers in London have demonstrated the ability of adult stem cells from bone marrow (mesenchymal stem cells, or MSCs) to deliver a cancer-killing protein to tumors.  The genetically engineered stem cells are able to home to the cancer cells, both in culture and in mouse models, and deliver TNF-related apoptosis-inducing ligand (TRAIL), destroying the tumor cells while sparing normal cells. …”

Continue reading →

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on Pinterest (Opens in new window) Pinterest
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Reddit (Opens in new window) Reddit
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email
Like Loading...
Posted in Medical Study Results, Meeting Highlights, Novel Therapies | Tagged adult stem cells, American Thoracic Society, Centre For Respiratory Research, Medical Research Council UK, mesenchymal stem cells, Michael Loebinger M.D. M.A., ovarian cancer, S.M. Janes M.D. Ph.D., TNF-related apoptosis-inducing ligand, TRAIL, University College of London, vector | Leave a comment
"Once you choose hope, anything is possible." -- Christopher Reeve

Categories

RSS Google Ovarian Cancer News

  • Michael Liontos Challenges Selective Evidence in KEYLYNK-001 Ovarian Cancer Trial - Oncodaily
  • Dana-Farber Expert Explains Rina-S Data in Platinum-Resistant Ovarian Cancer - Cure Today
  • PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - TradingView
  • Eldorado woman with breast, ovarian cancer dedicated to prevention work - Santa Fe New Mexican
  • Why doctors are urging women to redo early genetic tests for cancer risks - The Washington Post
  • Verastem Explores Avmapki Fakzynja Activity Outside of KRAS-Mutant Ovarian Cancer - GenomeWeb
  • Breast and ovarian cancer survivor shares her story - KARK
  • Ovarian Cancer’s Hidden Weakness: An Arginine Gateway on the Cell Surface - Bioengineer.org
  • “I get to live my life”: Nebraska woman joins ovarian cancer risk-reduction trial - University of Nebraska Medical Center
  • How New Science is Reshaping Ovarian Cancer Treatment and Care - American Association for Cancer Research

Top Posts

  • About
    About
  • PI3K Pathway:  A Potential Ovarian Cancer Therapeutic Target?
    PI3K Pathway: A Potential Ovarian Cancer Therapeutic Target?
  • 2009-2010 U.S. News & World Report Best U.S. Hospital Rankings
    2009-2010 U.S. News & World Report Best U.S. Hospital Rankings
  • The Mirror: "What is the Meaning of Life?"
    The Mirror: "What is the Meaning of Life?"
  • CNTO 328 Shows Promise For Ovarian Cancer In Small Clinical Trial, Say U.K. Scientists.
    CNTO 328 Shows Promise For Ovarian Cancer In Small Clinical Trial, Say U.K. Scientists.
  • Genetics
    Genetics
  • ASCO Releases Studies From Upcoming 2010 Annual Meeting
    ASCO Releases Studies From Upcoming 2010 Annual Meeting
  • Combination Targeted Therapy With Sorafenib & Bevacizumab Shows Antitumor Activity
    Combination Targeted Therapy With Sorafenib & Bevacizumab Shows Antitumor Activity
  • In-Depth Review: The Cancer Genome Atlas Reports On Landmark Analysis of High-Grade Serous Ovarian Cancer
    In-Depth Review: The Cancer Genome Atlas Reports On Landmark Analysis of High-Grade Serous Ovarian Cancer
  • Contact
    Contact

Archives

  • May 2015
  • September 2014
  • August 2014
  • May 2014
  • March 2014
  • August 2013
  • May 2013
  • February 2013
  • January 2013
  • July 2012
  • June 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008

Blog Stats

  • 513,899 Visitors
cancer blog

Enter your email address to subscribe to Libby's H*O*P*E* & receive notifications of new posts by email.

Join 342 other subscribers

 Subscribe in a reader

Click on the orange button above if you want to (i) add Libby's H*O*P*E*(tm) updates to a web-based or other reader, or (ii) embed a Libby's H*O*P*E* (tm) update widget on your desktop, website or blog.

Donate To Ovarian Cancer Research

OCRF is the largest U.S. private funding agency supporting ovarian cancer research. It is a not-for-profit, 501(c)(3) organization. Click on the OCRF logo above to make a donation.

Strategic Partners

Podcasts

Join Us In the Fight Against Ovarian Cancer

RSS New Ovarian Cancer Clinical Trials (Past 14 Days)

  • Blood Samples Were Taken From Patients Undergoing Oncological Treatment in Order to Validate the TST79 Molecular Test
  • Dermatological Effects and Quality of Life in Oncology Patients
  • Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery
  • Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer
  • Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
  • Contrast-enhanced Ultrasound Evaluation of Indeterminate Ovarian Lesions: Prospective Multicenter Study
  • Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer

RSS New Adult Solid Tumor Clinical Trials (Past 14 Days)

  • GST101 in Participants With RAS-Mutant Advanced Solid Tumors
  • Benefits of Nutritional Supplement in Cancer Care
  • Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
  • Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers
  • Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
  • Clinical Study of Three-dimensional Lattice Radiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Advanced Solid Tumors
  • Umbilical Cord Blood Infusion to Promote Hematopoietic and Immune Reconstitution in Children With Relapsed or Refractory Malignant Solid Tumors
  • A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy
  • Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC
  • Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors

RSS Medical Studies

  • Cystic-solid ADC difference on MRI for differentiating seromucinous borderline tumor from endometriosis-associated ovarian cancer
  • Integrated host vulnerability assessment using prognostic nutritional index and psoas muscle index for predicting chemotherapy-related toxicity in ovarian cancer: a multicenter JGOG9005S cohort analysis
  • Ultrasound features of neuroectodermal tissue in ovarian mature cystic teratomas
  • "TRACEBACK has probably saved my life": experiences of being notified about clinically significant cancer genetic information by the Australian TRACEBACK program
  • Comparison of outcomes between fertility-sparing and radical surgery in patients with pathological stage I epithelial ovarian cancer: a single-center retrospective cohort study
  • Beyond feasibility: an oncology-first framework for defining the role of robot-assisted surgery in ovarian cancer-patient selection, surgical adequacy, and conversion pathways
  • Plasma metabolomic profiles associated with breastfeeding history and subsequent ovarian cancer risk
  • Early experience with mirvetuximab soravtansine in the treatment of recurrent low- grade serous ovarian carcinoma
  • The miR-221-5p/RAD18/RAD51 Axis Regulates DNA Damage Tolerance and Homologous Recombination to Drive Platinum Resistance in Ovarian Cancer
  • BLTP3A dysfunction unleashes lysosomal stress-induced antitumor immunity through STING

Recent Comments

Prometey Bank's avatarPrometey Bank on World Ovarian Cancer Day: Toge…
mikaljhohnashly's avatarmikaljhohnashly on World Ovarian Cancer Day: Toge…
Jan C. Calthrop's avatarJan C. Calthrop on Lab-On-A-Chip: Veridex & M…
Paul Cacciatore's avatarPaul Cacciatore on About
Building a Team for… on About
Kathleen's avatarKathleen on About
Paul Cacciatore's avatarPaul Cacciatore on About
Liz's avatarLiz on About
Paul Cacciatore's avatarPaul Cacciatore on Dana Farber Webchat: The Lates…
Judith Marengere's avatarJudith Marengere on Dana Farber Webchat: The Lates…
Paul Cacciatore's avatarPaul Cacciatore on Dana Farber Webchat: The Lates…
Franca Pichini's avatarFranca Pichini on Dana Farber Webchat: The Lates…
painspeaks's avatarpainspeaks on SU2C Announces the Formation o…
marcy westerling's avatarmarcy westerling on SU2C Announces the Formation o…
anne's avataranne on Dana-Farber Oncologists Differ…

Blogroll

  • Site Meter Site Meter

Cancer Organizations

  • American Cancer Society
  • National Cancer Institute

Everyday Heroes

  • Are You There Cancer? It's Me, Jennie.
  • Bald Heads Are Sexy
  • Butterfly Ballet
  • Cancer Queen
  • Carrie's Journey
  • Chris Bledy
  • Diary of a Cancer Patient
  • I Want To Breathe
  • Janine's News
  • Journey Through Ovarian Cancer
  • Kristi & Brian: Living! With Cancer
  • Laurey Bikes
  • Life Cycle
  • livingly dying
  • Marcheline Bertrand Remembered
  • Meghan's Message
  • Monday Hearts For Madalene
  • My Journey With Teal
  • Nobody Has Ovarian Cancer
  • Out Shine Ovarian Cancer
  • OVACOM
  • Ovarian Cancer News
  • Ovarian Cancer?? pass the wine … now!
  • Scrambled Eggs, Surviving Ovarian Cancer
  • Shannon Miller Lifestyle
  • Still Smiling
  • Strong As Steele
  • Tenaciously Teal
  • The Carcinista
  • What? Me Worry?
  • Will There Be Cows In Heaven?
  • Women of Teal

Inspirational Cancer Advocates

  • Bald Is Beautiful
  • Bicycling For Ovarian Cancer (Craig Broeder)
  • Christine Druther
  • Fran Drescher
  • Imerman Angels
  • Jenn Sommermann: Training For a Cure
  • Jim Valvano
  • Laurey Masterton
  • Maddie Kullen
  • Mothers With Cancer
  • Randy Pausch
  • Sean Swarner
  • Standup2cancer
  • The Rock Band N.E.D.

Ovarian Cancer News Archive

  • Ovarian Cancer News Archive

Ovarian Cancer Organizations

  • National Breast & Ovarian Cancer Connection
  • National Ovarian Cancer Coalition
  • Ovarian Cancer National Alliance
  • Ovarian Cancer Research Fund
  • Ovations For the Cure

U.S. Treatment Centers

  • National Comprehensive Cancer Network Member Institutions
  • NCI-Designated Cancer Centers

Video Archive

  • Ovarian Cancer Video Library
Copyright 2008 - 2016 Paul Cacciatore, Libby's H*O*P*E*(TM), *Helping *Ovarian Cancer Survivors *Persevere Through *Education(TM), all rights reserved.
Paul Cacciatore

Create Your Badge
Site Meter
Blog at WordPress.com.
  • Subscribe Subscribed
    Libby's H*O*P*E*
    Join 217 other subscribers

    Have a WordPress.com account? Log in now.

  • Libby's H*O*P*E*
    View site in Reader
    Manage subscriptionsSign upLog in
    Report this content
    Collapse this bar
%d